炎症性肠病患者从静脉注射英夫利昔单抗改为皮下注射：一项受疫情驱动的举措。 - Suppr

Suppr

超能文献

From intravenous to subcutaneous infliximab in patients with inflammatory bowel disease: a pandemic-driven initiative.

作者信息

Verma Ajay M, Patel Anusha, Subramanian Sreedhar, Smith Philip J

机构信息

Department of Gastroenterology, Kettering General Hospital, Kettering NN16 8UZ, UK.

出版信息

Lancet Gastroenterol Hepatol. 2021 Feb;6(2):88-89. doi: 10.1016/S2468-1253(20)30392-7.

DOI:10.1016/S2468-1253(20)30392-7

PMID:33444534

Abstract

摘要

相似文献

From intravenous to subcutaneous infliximab in patients with inflammatory bowel disease: a pandemic-driven initiative.炎症性肠病患者从静脉注射英夫利昔单抗改为皮下注射：一项受疫情驱动的举措。

Lancet Gastroenterol Hepatol. 2021 Feb;6(2):88-89. doi: 10.1016/S2468-1253(20)30392-7.

Can Subcutaneous Infliximab Replace Dose-Intensified Intravenous Administration in Inflammatory Bowel Disease?皮下注射英夫利昔单抗能否替代剂量强化的静脉给药用于治疗炎症性肠病？

Clin Gastroenterol Hepatol. 2023 Aug;21(9):2430-2431. doi: 10.1016/j.cgh.2022.09.015. Epub 2022 Sep 22.

[Biological drugs in inflammatory bowel disease: Management and care].[炎症性肠病中的生物药物：管理与护理]

Rev Esp Enferm Dig. 2015 Jul;107(7):454.

Shot Heard Around the World? Subcutaneous Infliximab as Maintenance Therapy for Inflammatory Bowel Disease.举世瞩目的注射？皮下注射英夫利昔单抗作为炎症性肠病的维持治疗

Gastroenterology. 2024 Oct;167(5):841-842. doi: 10.1053/j.gastro.2024.07.005. Epub 2024 Jul 14.

Adherence to intravenous biological treatment in inflammatory bowel disease patients during the COVID-19 pandemic.COVID-19 大流行期间炎症性肠病患者静脉内生物治疗的依从性。

Rev Esp Enferm Dig. 2021 Feb;113(2):154. doi: 10.17235/reed.2020.7562/2020.

Switching From Intravenous to Subcutaneous Infliximab is Safe and Feasible in Patients With Inflammatory Bowel Disease Suffering From Obesity: A Post Hoc Analysis of the REMSWITCH Study.从静脉输注切换至皮下注射英夫利昔单抗在肥胖的炎症性肠病患者中是安全且可行的：REMSWITCH 研究的事后分析。

Clin Gastroenterol Hepatol. 2024 May;22(5):1127-1129.e2. doi: 10.1016/j.cgh.2023.09.027. Epub 2023 Oct 4.

Switching from Dose-Intensified intravenous to SubCutaneoUS infliximab in Inflammatory Bowel Disease (DISCUS-IBD): protocol for a multicentre randomised controlled trial.从强化静脉注射英夫利昔单抗转换为皮下注射英夫利昔单抗治疗炎症性肠病（DISCUS-IBD）：一项多中心随机对照试验方案。

BMJ Open. 2024 Jul 20;14(7):e081787. doi: 10.1136/bmjopen-2023-081787.

Transitioning patients from intravenous to subcutaneous infliximab and vedolizumab for inflammatory bowel disease: what is the opportunity cost of improving access to healthcare?将炎症性肠病患者从静脉注射英夫利昔单抗和维得利珠单抗转换为皮下注射：改善医疗保健可及性的机会成本是什么？

Intern Med J. 2024 Jun;54(6):970-979. doi: 10.1111/imj.16311. Epub 2024 Jan 12.

Budget impact analysis of subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in Saudi Arabia: Analysis from payer perspective.沙特阿拉伯治疗炎症性肠病的皮下注射英夫利昔单抗（CT-P13 SC）的预算影响分析：支付方视角的分析。

PLoS One. 2024 Nov 12;19(11):e0312603. doi: 10.1371/journal.pone.0312603. eCollection 2024.

Alternative strategies for the use of infliximab in pediatric inflammatory bowel disease.英夫利昔单抗在儿童炎症性肠病中的替代使用策略。

Curr Gastroenterol Rep. 2008 Jun;10(3):302-7. doi: 10.1007/s11894-008-0060-5.

引用本文的文献

Barriers, Drivers, and Outcomes in Transitioning Patients With Inflammatory Bowel Disease From Intravenous to Subcutaneous Infliximab.炎症性肠病患者从静脉注射英夫利昔单抗转换为皮下注射英夫利昔单抗的障碍、驱动因素及结果

Crohns Colitis 360. 2025 Jul 20;7(3):otaf008. doi: 10.1093/crocol/otaf008. eCollection 2025 Jul.

Machine Learning in Primary Health Care: The Research Landscape.初级卫生保健中的机器学习：研究概况

Healthcare (Basel). 2025 Jul 7;13(13):1629. doi: 10.3390/healthcare13131629.

Did We Overreact? Insights on COVID-19 Disease and Vaccination in a Large Cohort of Immune-Mediated Inflammatory Disease Patients during Sequential Phases of the Pandemic (The BELCOMID Study).我们反应过度了吗？大流行各阶段大量免疫介导炎症性疾病患者中新冠疾病与疫苗接种的见解（BELCOMID研究）

Vaccines (Basel). 2024 Oct 11;12(10):1157. doi: 10.3390/vaccines12101157.

Impact on direct and indirect costs of switching patients with inflammatory bowel disease from intravenous to subcutaneous infliximab (CT-P13).切换炎症性肠病患者从静脉注射用英夫利昔单抗（CT-P13）至皮下注射用英夫利昔单抗对直接和间接成本的影响。

BMJ Open Gastroenterol. 2023 Feb;10(1). doi: 10.1136/bmjgast-2023-001105.

Customer-centric product presentations for monoclonal antibodies.以客户为中心的单克隆抗体产品展示。

AAPS Open. 2023;9(1):3. doi: 10.1186/s41120-022-00069-y. Epub 2023 Jan 23.

The Effects of the COVID Pandemic on Patients with IBD: Lessons Learned and Future Directions.新冠疫情对炎症性肠病患者的影响：经验教训与未来方向

J Clin Med. 2022 Nov 27;11(23):7002. doi: 10.3390/jcm11237002.

Uptake of a Switching Program for Patients Receiving Intravenous Infliximab and Vedolizumab to Subcutaneous Preparations.接受静脉注射英夫利昔单抗和维多珠单抗治疗的患者改用皮下制剂的转换方案采用情况。

J Clin Med. 2022 Sep 26;11(19):5669. doi: 10.3390/jcm11195669.

Subcutaneously-Administered Infliximab in the Management of Rheumatoid Arthritis: A Short Narrative Review of Current Clinical Evidence.皮下注射英夫利昔单抗治疗类风湿关节炎：当前临床证据的简短叙述性综述

J Inflamm Res. 2022 Jun 1;15:3259-3267. doi: 10.2147/JIR.S240593. eCollection 2022.

Re-Routing Infliximab Therapy: Subcutaneous Infliximab Opens a Path Towards Greater Convenience and Clinical Benefit.重新调整英夫利昔单抗治疗方案：皮下注射英夫利昔单抗为患者提供了更便捷和更有益的治疗选择。

Clin Drug Investig. 2022 Jun;42(6):477-489. doi: 10.1007/s40261-022-01162-6. Epub 2022 Jun 3.

Recent advances in clinical practice: management of inflammatory bowel disease during the COVID-19 pandemic.临床实践新进展：COVID-19 大流行期间炎症性肠病的管理。

Gut. 2022 Jul;71(7):1426-1439. doi: 10.1136/gutjnl-2021-326784. Epub 2022 Apr 27.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验